Mirum Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Mirum Pharmaceuticals

26/02/2025 22:02

Mirum Pharmaceuticals Inc MIRM.OQ reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -66 cents.  The mean expectation of nine analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -41 cents to -12 cents per share.

Revenue rose 42.9% to $99.41 million from a year ago; analysts expected $96.61 million.

Mirum Pharmaceuticals Inc's reported EPS for the quarter was a loss of 49 cents​.

The company reported a quarterly loss of $23.79 million.

Mirum Pharmaceuticals Inc shares had risen by 20.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 13.8% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $64.50

This summary was machine generated from LSEG data February 26 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.24
-0.49
Missed
Sep. 30 2024
-0.45
-0.30
Beat
Jun. 30 2024
-0.47
-0.52
Missed
Mar. 31 2024
-0.48
-0.54
Missed